Latest filing published 18 Jun 2020 for Aprea Therapeutics, Inc., €3.4M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -78.8%Entry US$2,070.00 · Close at T+365 US$438.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Scott M. Rocklage: trading record in brief
Scott M. Rocklage discloses dealings in 5 companies, chiefly Relypsa Inc, Aprea Therapeutics, Inc. and Pulmatrix, Inc. Over a trading history stretching from 20 November 2013 to 16 June 2020, the count stands at 54 filings.
In open-market terms, that means 6 purchases worth €5.0M on one side and 6 sales worth €18.0M on the other. Netting one side against the other leaves €13.0M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 12 share grants and 10 option exercises. So far in 2020, the count stands at no purchases and 6 sales.
A typical purchase (the median) is worth €142k.
On 18 June 2020 came the latest disclosure, an open-market sale for €3.4M in Aprea Therapeutics, Inc. The most recent open-market purchase was published on 17 June 2015, 4,162 days ago. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Scott M. Rocklage
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 115,357 shares@ US$33.30Common StockSEC:0001209191-20-037715:0
- 4,807 shares@ US$33.30Common StockSEC:0001209191-20-037715:1
- 235,200 shares@ US$28.75Common StockSEC:0001209191-20-036847:0
- 9,800 shares@ US$28.75Common StockSEC:0001209191-20-036847:1
- 244,800 shares@ US$35.15Common StockSEC:0001209191-20-031546:0
- 10,200 shares@ US$35.15Common StockSEC:0001209191-20-031546:1
- 1,913,910 sharesCommon StockSEC:0001140361-19-018083:0
- 79,746 sharesCommon StockSEC:0001140361-19-018083:1
- 492,475 sharesCommon StockSEC:0001140361-19-018083:2
- 20,519 sharesCommon StockSEC:0001140361-19-018083:3
- 164,058 sharesCommon StockSEC:0001144204-15-037761:2
- 1,158,164 sharesCommon StockSEC:0001144204-15-037761:0
- 33,990 shares@ US$6.88Common StockSEC:0001144204-15-037761:1Canonical exit: 14 Sept 2015 (T+90)
- 4,815 shares@ US$6.88Common StockSEC:0001144204-15-037761:3Canonical exit: 14 Sept 2015 (T+90)
- 1,764,195 sharesCommon StockSEC:0001209191-15-035568:0
- 45,467 sharesCommon StockSEC:0001209191-15-035568:1
- 757,187 sharesCommon StockSEC:0001181431-13-060007:0
- 568,542 sharesCommon StockSEC:0001181431-13-060007:1
- 576,958 sharesCommon StockSEC:0001181431-13-060007:2
- 207,347 sharesCommon StockSEC:0001181431-13-060007:3
- 47,849 sharesCommon StockSEC:0001181431-13-060007:4
- 37,056 shares@ US$9.1848Common StockSEC:0001181431-13-060007:5
- 30,942 shares@ US$11.00Common StockSEC:0001181431-13-060007:6
- 74,281 shares@ US$0.17Common StockSEC:0001181431-13-060007:7
- 1,162 shares@ US$11.00Common StockSEC:0001181431-13-060007:8
25 of 47 declarations
